On the evening of June 24th, Chongqing Pharscin Pharmaceutical (002907) announced that the company recently received the "Pharmaceutical Production License" issued by the Chongqing Drug Administration. This change mainly involves reducing commissioned production. The commission party for this reduction is Chengdu Tongde Pharmaceutical Co., Ltd., and the commissioned varieties are injection omeprazole sodium and injection methyl sulfonyl guanidine. The commission is valid until October 30, 2025. This reduction in commissioned production indicates that injection omeprazole sodium and injection methyl sulfonyl guanidine will be produced by the company itself, which is beneficial for the company to control the quality of the products and improve the utilization rate of the company's production capacity. This change will not have a significant impact on the company's performance in the short term, but market development in the future is uncertain.
华森制药：公司药品生产许可证变更 核减委托生产
Chongqing Pharscin Pharmaceutical: Change in the company's pharmaceutical production license, reducing commissioned production.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.